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Abstract  
The large number of probiotic products now available makes the decision about which 
product to choose difficult both for the consumer and for the specialist providing 
dietary/nutritional advice. Data on the viability of the bacteria in these products, in the in-vivo 
situation, are therefore important. This study was designed to explore the comparative health 
and survival of probiotic species in various commercial formulations, using more realistic test 
systems that might allow further understanding of factors that must be controlled to give the 
greatest chance of delivery of live healthy bacteria to the lower gut. 
A total of eight commercially available probiotic preparations were selected for enumeration 
tests and in-vitro gastric tolerance tests. Tolerance assays were conducted in porcine gastric 
fluid (PGF) fed and fasted state (pH 3.4 ± 0.04), simulated gastric fluid (SGF, pH adjusted to 
1.2 and 3.4) and fasted state simulated gastric fluid (FaSSGF, pH adjusted to 1.6 and 3.4). 
Isothermal microcalorimetry was also used to measure real-time growth of probiotics after 
exposure to simulated gastric fluid. 
Results from the enumeration tests indicated that recovery of viable organisms per dose is the 
same as or better than the stated label claims for liquid-based formulations but lower than the 
stated claim for freeze-dried products. Results from the in-vitro tolerance tests overall suggest 
that the PGF provided a harsher environment than the simulated systems at similar pH.  In 
general, liquid-based products tested tended to give superior results in terms of survival 
compared with the freeze-dried products tested.  Results from tests in the fed state in PGF 
suggested that food greatly affects viability. Microcalorimetric data showed that for some 
products probiotic species were able to grow following exposure to gastric fluid, suggesting 
that viable bacteria reach the gut in-vivo. 
Keywords: Gastric tolerance, Lactobacillus, Survival, Viability, Gastric fluid 
3	  
	  
Introduction 
Probiotics have become a huge commercial success story in recent years; in 2006 it was 
estimated that the UK population spent £189 million on probiotics (Food Commission 2006) 
and the global market for these products is forecast to be worth US$32.6 billion in 2014 
(Cook et al. 2012). At the same time, the number of clinical trials investigating the use of 
probiotics has also seen a huge increase; a simple search on PubMed shows that between 
1992 and 2002, a total of 113 clinical trials on probiotics were published, yet from 2002 to 
2012, this number had increased ten-fold to 1041 (PubMed 2013). The large numbers of 
probiotic products available makes the decision about which product to choose ever more 
difficult both for the consumer and for the specialist providing dietary/nutritional advice. 
Data on the health and survival of the bacteria in these products, measured in experiments 
that most closely mimic the in vivo situation are therefore important. 
The term probiotic encompasses all ‘live microorganisms that when administered in adequate 
quantities confer a health benefit on the host’; this definition, agreed by the FAO and WHO 
(FAO/WHO 2001; 2002), assumes viability of the bacterial content of each probiotic product; 
i.e. that an appropriate number of bacteria survive transit through the gastrointestinal (GI) 
tract and are fully able to grow and colonise in the colon on arrival. Although there is no 
global agreement on the minimum number of bacteria per gram or millilitre of product 
necessary for functionality, it is generally accepted that at the point of consumption, probiotic 
products should have a minimum concentration of >1 x 106 colony forming units (CFU)/mL 
or gram and that a total of some 108 to 109 probiotic microorganisms should be consumed 
daily if therapeutic effects are to be realised (Minelli and Benini 2008). Again, these 
definitions assume that these are live, healthy bacteria at the point of consumption. The 
concentration of live, healthy bacteria in the colon that are necessary to confer therapeutic 
benefits is unknown yet is clearly important. 
The health and survival of bacteria in probiotic products in the range of environments they 
will encounter in use (during manufacture, storage, transit through the stomach and arrival at 
the small intestine) is critical in ensuring potential effectiveness. Of these, transit through the 
gut potentially induces the greatest loss in viable organisms. The main physical and chemical 
barriers of the GI tract include pH, volume, composition and buffer capacity of the gastric 
juice, transit time and the presence of foods. The dose and formulation of the probiotic can be 
optimised to mitigate the effects of some or all of these factors. 
Gastric juice is a crucial barrier to most pathogens; it displays large variability in 
characteristics under different conditions, for example during the fed and fasted states (Evans 
et al. 1988; Fordtran and Walsh 1973). Under fasted conditions the pH in a healthy human 
stomach is acidic, generally ranging between 1 and 3 (Dressman et al. 1990; Kalantzi et al. 
2006). After food, the stomach environment varies considerably over the course of gastric 
residence of the meal (Kalantzi et al. 2006), the pH climbing briefly to a median peak value 
of 6.7 before declining back to the fasted state value within two hours or less (Dressman et al. 
1990). The stomach also displays large variability in emptying times between fed and fasted 
states (and within these states there are also large inter-individual variations); in general, 
emptying times in the fasted state are considerably quicker (mean ± SD of half gastric 
emptying time (t1/2) 80.5 ± 22.1 minutes) than those in the fed state (median time of t1/2127 
minutes (25–75% percentiles: 112.0–168.3 minutes) (Hellmig et al. 2006)) and in general 
water-based liquids traverse faster than non-water-based particularly in the fasted state; non-
nutrient liquids do not normally interrupt the migrating myoelectric complex and are typically 
emptied in an exponential pattern (Steingoetter et al. 2006). Studies have shown the half-time 
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for saline emptying from the human stomach to be approximately 12 minutes (Granger 1985), 
and the half-time for emptying water to be in the region of 15-16 minutes (Steingoetter et al. 
2006). There is also variability in complexity of chemical constituents such as bile salts and 
proteolytic enzymes and in the volume of the gastric contents; the capacity of the stomach 
has been noted to be 1.5 L (Aulton, 2013) but can contain up to 63 mL of free fluid in the 
fasted state (McConnell  et al. 2008).  
The human stomach is known to have an ionic strength of 0.1 ± 0.025 mM and 
concentrations of potassium, sodium, chloride, calcium, at 13.4 ± 3.0 mM, 68 ± 29 mM, 102 
± 28 mM, and 0.6 ± 0.2 mM respectively (Lindahl et al. 1997). Its bile salt concentration is 
approximately 0.06 mM in the fed (Rhodes 1969) and 0.2 ± 0.2 mM in the fasted state 
(Lindahl et al. 1997). To date, various media have been developed to simulate the fasted 
gastric content (British Pharmacopoeia 2012; FDA 2000; United States Pharmacopoeia 
2000). Often, these media try to mimic the salt concentration of the gastric juice through the 
addition of up to 0.5% w/v of sodium chloride to HCl (Charteris et al. 1998). Surface tension 
and bile content is also simulated through the addition of bile salt, pepsin and/or surfactants 
to HCl (Aburub et al. 2008; Vertzoni et al. 2005). Addition of these has changed the 
solubility and dissolution of drugs and has often been recommended in dissolution fluids 
(Mudie et al. 2010; Nicolaides et al 1999).  
Gastric tolerance assays for potential new probiotic formulations (Chandramouli et al. 2004; 
Cook et al. 2011; Cui et al.  2000; Ding et al. 2009; Mokarram et al. 2009) and commercial 
probiotic products (Sahadeva et al. 2011) or organisms (Jensen et al. 2012) routinely use 
either buffer or saline solutions adjusted to pH 1.2 to 4, or growth media, adjusted to these 
same pH’s, to simulate the gastric juice. These simulated fluids often lack the complexity of 
real gastric fluid and gastric volumes are often not accounted for or ignored.  
Gastric tolerance assays frequently use the plate count technique to assess the survival of 
bacteria after exposure. While this is a useful and widely accepted technique it does have 
inherent problems; it is extremely labour intensive and time-consuming and can result in 
overestimation or underestimation of numbers of viable organisms. For example, stress 
during plating can cause underestimation of numbers; organisms may be unevenly distributed 
on the plate and may occur in chains and/or clumps. The surface of an agar plate may also be 
a difficult place for some organisms to start growth after being removed from their natural 
milieu (Lydell et al. 2002), while some organisms may be difficult to grow on a plate relative 
to a liquid medium. For those organisms that thrive on agar, plate counting is still not a 
suitable model for assessment of in-vivo growth, because the plate is designed to provide a 
nutrient-rich environment to support growth to enable visual counting.  By so doing it can 
skew results by allowing any surviving bacteria to grow and recover in an environment that 
does not mimic the continuing harsh in vivo situation where, in the case of probiotics, any 
surviving bacteria would go on to face transit through the small intestine.  
An alternative, real-time measurement of viability would be a significant improvement for 
assessing likely in-vivo efficacy of probiotic products. One option is isothermal 
microcalorimetry (measurement of the rate of heat production, or power, as a function of time 
at constant temperature, O’Neill and Gaisford, 2011). As microcalorimeters are able to 
measure heat production rates of less than a microwatt they can measure the metabolism and 
growth of relatively small numbers of bacteria (as low as 104 - 105 CFU/mL depending on 
species, Braissant et al. 2009). Because dissimilar bacterial species utilise nutrients via 
different metabolic pathways, the power-time curve is indicative of species and can be used 
for bacterial identification (Boling et al, 1973). An additional benefit is that there is no 
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requirement for optical clarity in the growth medium and so growth rates can be determined 
directly in opaque fluids (Said et al, 2014). 
This study was designed to explore the comparative health and survival of probiotic species 
in various commercial formulations, using an experimental approach to mimic oral delivery. 
It set out to investigate the concentrations of bacteria present in selected products at the point 
of consumption and to measure survival, using plate-count techniques, following exposure to 
three different gastric fluids to explore the importance of using bio-relevant test systems. 
Lastly it investigated the use of microcalorimetry to measure real-time survival of probiotics 
following exposure to simulated gastric fluid. The overall objectives were to develop more 
realistic test systems, to understand further the factors that must be controlled in delivering 
live healthy species to the lower gut and to recommend to consumers best practice in taking 
probiotic supplements.  
Materials and methods 
A total of eight commercially available probiotic preparations (Table 1) were selected for 
study. All were purchased from local supermarkets or pharmacies or obtained from the 
manufacturers or distributors.  All were stored according to label and all were used for study 
before their expiry dates. 
Enumeration of viable organisms in probiotic products 
De Man Rogosa Sharpe (MRS) agar (Oxoid) containing 0.05% w/v L-cysteine hydrochloride 
“MRSc” was used as the growth medium.  The content of a capsule or sachet of the freeze-
dried products were dispersed in 10 mL sterile phosphate buffered saline (PBS) (pH 7.4). The 
mixture was then vortexed to homogeneity, serially diluted in PBS and spread-plated on 
MRSc agar. Liquid products were serially diluted and spread-plated on MRSc agar. All plates 
were then incubated at 37 oC in anaerobic jars (Oxoid) using the Anaerogen GasPak System 
(Oxoid). Colonies were counted after incubation for 48 hours. 
The actual contents of a dose of these products were calculated using the formula:  
Actual content (CFU/dose) = (CFU/mL) * dose 
For a solid (dried) product, content per capsule or sachet = (CFU/mL) * 10 mL, for a liquid 
product, content per dose = (CFU/mL) * recommended volume 
All enumeration experiments were performed in triplicate and CFU values were expressed as 
log values.  
Preparation of gastric fluids 
Three types of gastric fluid were used for study; porcine gastric fluid (PGF), simulated gastric 
fluid (SGF) and fasted state simulated gastric fluid (FaSSGF). 
PGF was obtained from an abattoir from a freely fed, adult animal. Juices were dispensed 
into multiple aliquots and frozen at -80 oC.  Prior to use, they were thawed at room 
temperature, and then centrifuged at 10000rpm (Mini spin, Eppendorf, Germany) for 10 
minutes at 25 oC. The supernatant obtained was sterilized by filtration using a membrane 
filter of 0.22 µm pore size.  
SGF was prepared by adding HCl (Sigma Aldrich, 37%) to a solution of NaCl (2 g/L, AnalaR 
BDH 58.44g/mol) and adjusting the pH (pHenomenal®, UK) to either 1.2 ± 0.1 or 3.4 ± 0.1.  
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FaSSGF was prepared according to the composition presented by Vertzoni et al (2005) with 
SIF® powder (Biorelevant Ltd). NaCl (2 g) was dissolved in purified water (1 L) and the pH 
adjusted to either 1.6 ± 0.1 or 3.4 ± 0.1 as appropriate with HCl. A total of 0.06 g of SIF® 
powder was added to the prepared HCl/NaCl solution to a volume of 1L to give a final 
composition of sodium taurocholate 80 µM; lecithin 20 µM; pepsin 0.1 mg/ml; sodium 
chloride 34.2mM. All artificial juices were used within 48 hours of preparation. 
Measurement of surface tension, osmolality, pH and buffer capacity of the gastric fluids 
The surface tensions of the gastric fluids were measured using the du Noüy-Paddy method 
(Delta-8 automatic multichannel microtensiometer, Kibron Inc., Finland). The temperature of 
the instrument was between 27.7-27.9 oC. Measurements were made on 50 µL/wells of 8 
samples of each fluid in 96-well plates. Calibration was performed with deionized water prior 
to the experiments.  
Osmolality of the fluids was measured using the freezing point depression technique with a 
digital micro-osmometer, (Hermann Reobling Messtechnik, Germany) on 100 µL samples. 
Calibration was undertaken with deionized water and measurements made in triplicate.  
The buffer capacities of the fluids were measured by adding NaOH standard solution (0.1 M) 
to each fluid (3 mL) and noting the volume of NaOH needed to change the pH by 0.5 units.  
Buffer capacities were determined using the equation;  
β (mmol/L/∆pH) = ∆AB/∆pH  
where ∆AB is the small increment in mol/L of the amount of acid or base added to produce a 
pH change of ∆pH in the buffer. This equation can be rewritten as;  
β (mmol/L/∆pH) = ∆AB/∆pH = ((Ma x Va)/∆pH) x 1000/Vb  
where Ma  is the molarity of the acid, Va is the volume of acid in mL, Vb is the volume of 
buffer in mL, ∆pH is the change in pH. The equation is multiplied by 1000 to express the 
volume in litres. 
Measurement of the in-vitro gastric tolerance of probiotics in the fasted state 
For these tests it was assumed that the fasted stomach has a fluid capacity of 60 mL 
(McConnell 2008). The probiotics were mixed with SGF or FaSSGF (60 mL) to simulate in-
vivo conditions upon ingestion.  Doses of commercial products were as follows: 
• Symprove (60 mL) 
• Actimel and Yakult (entire bottle, 100 and 65 mL respectively) 
• Align, Bio-kult, Biobalance Support, Probio 7 and VSL#3 (entire content of 
capsule/sachet). 
For the bio-relevant test, probiotics were mixed with PGF in a ratio representative of the 
artificial fluids to the probiotics (1.5 mL PGF was mixed with: Align 4.4 mg; Biobalance 
support 7.5 mg; Bio-kult 4.4 mg; Probio7 11 mg; VSL#3 111.7 mg; Actimel 2.5 mL; 
Symprove 1.5 mL or Yakult 1.63 mL) and the mixture was vortexed at maximum speed for 
10 seconds.  
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All samples were incubated at 37 oC and aliquots of 50 µL were withdrawn at 5, 10, 20, and 
30 minutes, serially diluted in PBS and plated on MRSc agar for the determination of viable 
counts.  
Measurement of the in-vitro gastric tolerance of probiotics in the fed state in PGF 
For these tests it was assumed that the fed stomach had a fluid capacity of 1.5 L (Aulton 
2013). A representative dose of the probiotics was mixed with PGF in a ratio depictive of in-
vivo situation upon ingestion. The total volume of porcine fluid used was 1.5 mL. Thus 60 
µL, 100 µL and 65 µL of Symprove, Actimel, Yakult and 0.174 mg of Align, 0.300 mg of 
Biobalance Support, 0.171 mg of Bio-kult, 0.439 mg of Probio 7 and 4.45 mg of VSL#3 were 
weighed and all probiotics were added to PGF in a 1.8 mL micro tube.  The mixture was 
vortexed at maximum speed for 10 seconds and incubated at 37 oC. Aliquots of 50 µL were 
withdrawn at 5, 10, 20, 30, 90, 120 and 180 minutes, serially diluted in PBS and plated on 
MRSc agar plates for the determination of viable counts. 
Microcalorimetric gastric tolerance assay 
Probiotics were exposed to PGF mimicking the fasted state for 30 minutes prior to testing. 
Inoculua (30 µL) were added to MRSc (2.97 mL, pre-warmed to 37 oC). Experiments were 
performed in a 2277 Thermal Activity Monitor (TAM, TA Instruments Ltd) operated at 37 
oC. Samples were accurately pipetted into glass ampoules (3 mL). Ampoules were sealed 
with a crimped aluminium cap, a rubber disc ensuring an air-tight enclosure. Ampoules were 
placed into the loading position of the TAM and allowed to reach thermal equilibrium (30 
minutes) before being lowered into the measuring position. Data were recorded (1 point every 
10 seconds) with the dedicated software package Digitam 4.1. An ampoule containing buffer 
(3 mL) was used as a reference. The amplifier setting was 1000 µW and the instrument was 
calibrated with the electrical substitution method prior to first use.   
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Results 
Results from the enumeration tests of viable organisms per dose are shown in Figure 1. They 
indicate that for the liquid-based products recovery of viable organisms per dose is the same 
as or better than the stated label claims. For the freeze-dried products the results show that 
viable content was generally lower than the stated claim. 
The characteristics of the simulated gastric fluids and PGF are given in Table 2 and compared 
with published results for human gastric fluid. These results highlight the considerable 
differences between human gastric fluid, PGF and the two simulated fluids and show that 
PGF more closely resembles the osmolality, buffer capacity and surface tension of human 
gastric fluid than simulated fluids. 
Results from the in-vitro tolerance tests in the fasted state at similar pH are given in Figure 2 
for all test systems at pH 3.4. The results highlighted important differences between PGF, 
SGF and FaSSGF, particularly evident for some products. In all systems, all probiotics with 
the exception of one liquid-based product, showed a decline in viability during the first five 
minutes, probably as a result of acid shock. The results from tolerance testing at the lower pH 
for SGF (1.2) and FaSSGF (1.6) are given in Figure 3, where similar trends are seen.  
Results from the in-vitro tolerance test in PGF in the fed state are presented in Figure 4. In 
general, the liquid-based products retained viability better than the freeze-dried products (the 
exception being VSL#3). The water-based product exhibited the best tolerance to PGF 
relative to the other products in the fed state.  
Results from the microcalorimetric gastric tolerance assay are given in Figures 5 and 6. 
Figure 5 shows the characteristic calorimetric output plotted as power versus time from the 
different probiotics, while Figure 6 represents growth curves (plotted as cumulative heat 
versus time, discussed below) because this provides a better correlation with conventional 
optical density data (Braissant et al, 2011).  
Discussion 
The results are important for several reasons: they suggest that for many commercially 
available probiotics, claimed content and actual viability may not always be the same; they 
suggest that current simulated fluids used for gastric tolerance testing show a considerable 
difference from human gastric fluid, highlighting the importance of using bio-relevant testing 
systems; and they also suggest that real-time estimation of bacterial viability and growth is 
possible using microcalorimetry and that this technique may give further insight into 
comparative gastric survival.  
Results from the enumeration tests showed that the claimed content and actual viable cells in 
terms of CFUs per dose differ in many of the commercial products tested and that in 
particular, the freeze dried preparations tested had a lower viable content than stated claims. 
While freeze-drying is a commonly used method to preserve bacterial strains, its 
effectiveness is species-dependent and failures in viability have been reported (Stoianova and 
Arkad’eva, 2000). It has been shown that it is the dehydration stage that results in loss of 
viability (Harrison and Pelczar, 1963). Further, control of the rehydration stage is critical to 
maximise recovery, but this will vary from consumer to consumer. Ultimately, the potential 
efficacy of the products could be affected; amongst all the products tested, only the water-
based product showed recovery close to 100% in respect of the ratio of claimed to actual 
content.  
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Overall our findings suggest that the PGF provided a harsher environment than the simulated 
systems at similar pH, possibly as a result of the enzymatic and digestive substance 
composition of the gastric fluid.  Even when the simulated systems were used at a pH more 
consistent with the human stomach, survival was better than in PGF, again illustrating the 
harsher environment of PGF.  
Measurements of surface tension, osmolality, pH and buffer capacity of the gastric fluids also 
illustrate the relevance of using a more bio-relevant fluid for gastric tolerance testing; PGF 
more closely resembled human gastric fluid than the other two simulated fluids at two 
different pH levels. Our results from the PGF system may therefore be more important in 
terms of relevant results for decisions about which product to use. The in-vitro tolerance tests 
in the fasted state in PGF indicate that the liquid-based products tend to give superior results 
in terms of survival compared with the freeze dried products. There appears to be one 
exception to this rule (VSL#3) which is addressed in more detail below. Further tests were 
undertaken with solid products that were hydrated prior to exposure to the gastric fluids (data 
not shown), but the results suggested that re-hydration of dried products did not necessarily 
alter their viability for the better.  In general, the viability of products in the fasted state was 
improved relative to the fed state; however, results from the fed state model, based on normal 
gastric transit times at 90-180 minutes in the fed state, might give more relevant results for 
the way some probiotics are taken in real-life; many consumers choose to take them with 
food and many recommend that they be taken with food. Results from the in-vitro tolerance 
tests in the fed state in PGF suggest that food greatly affects viability; the different products 
reacted differently and of all products tested, the water-based product gave the best results.  
One observation from the fasted test systems was the effect of pH shock on the probiotics 
from zero to five minutes. In general, liquid products fared better than solid products, 
probably a result of several factors, including volume and/or the effects of other excipients. 
For instance, one bottle of Actimel contains 100 mL of product; quite adequate to dilute the 
stomach acid in the fasted state. Addition of SGF (pH 1.2) to Actimel increased the pH of the 
final mixture to 3.30.   Symprove depends on germinated barley, a prebiotic not digested by 
pancreatic enzymes, for protection of its bacteria against the harsh environment of the 
stomach. Actimel and Yakult are fermented milk products, which utilise milk proteins for 
protection. Dispersion of the solid products in SGF does not significantly alter pH. 
An additional consideration is that the excipients in the liquid products may also aid 
recovery, growth and adhesion of bacteria upon arrival in the small intestine. The fat content 
in milk products may offer further protection during passage through the GI tract 
(Ranadheera et al. 2012); a small study has highlighted this by showing significant reductions 
of L. casei DN-114 001 within Actimel Fat Free (0.428 ± 0.059 log10 CFU/mL), after five 
hours of simulated gastrointestinal transit (p<0.05), compared with insignificant reductions 
for Actimel Original (Wills 2012).  
One drawback of plate-counting was the inability to test bacterial viability in real-time; the 
technique relies on incubation of samples for 48 hours prior to counting. This means that for 
those products with very large numbers of bacteria in each dose, enough will survive to 
multiply in large numbers in this idealised environment. Isothermal microcalorimetry 
provides a real-time indication of growth, which may correlate better with what is happening 
in-vivo during gastric transit. Following exposure to PGF, samples were inoculated into 
growth medium and the growth patterns were measured. It is important to note here that the 
aim was to use calorimetry to determine viability after exposure to gastric acid, and so a 
growth medium was used to maximise growth. In vivo, bacteria would transit to the small 
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intestine and so be exposed to intestinal fluid in which growth would be different. The raw 
power output from a calorimeter is a plot of power (J/s, or W) versus time (s). As the bacteria 
in the sample grow and divide, the power produced will increase, resulting in a series of 
peaks and troughs as the organisms utilise available nutrients, Figure 5. The sequence of 
peaks and troughs is characteristic of species (Said et al. 2014). Conversion of the data to area 
under curve (cumulative heat, J) as a function of time, results in a growth curve identical in 
shape to that conventionally produced from optical density measurements (Braissant et al, 
2011), Figure 6. The growth rate of the bacterium is reflected in the gradient of the line 
(higher gradient indicating faster growth). It is important to note here that the initial inoculum 
number of bacteria will vary between products and that the minimum concentration of 
bacteria necessary to produce a measureable power is ca.104 - 105 CFU/mL. The lag time 
before growth implies either that bacterial numbers are below this value or that the organisms 
experience a degree of stress when inoculated into a new medium (the species in each 
product may react to environmental stress differently). 
The data in Figures 5 and 6 show that growth was fastest with Symprove and VSL#3. In the 
case of Symprove, this finding correlates with the stability data discussed earlier, the 
germinated barley providing both acid protection and a nutrient source. The finding in the 
case of VSL#3 is more surprising, given the significant loss of viable bacteria during 
exposure to SGF. One observation is that the growth curves of the two products were very 
similar; it may be the case that the majority of the species in VSL#3 are killed by the low pH 
in SGF, but the lactobacilli survive. Symprove contains three lactobacilli species and so the 
growth curves of both products are similar. The next fastest growth is seen in Actimel and 
Yakult, again in accordance with the viability in SGF data discussed earlier. Some growth is 
seen in Bio-kult and Biobalance, but not until at least 30 hours; it is likely that in-vivo these 
products would have been excreted within this time frame. 
Overall our study is the first to provide comparative data on actual products in situations that 
most closely mimic what is happening in the human GI tract. The only similar study to our 
knowledge was undertaken by the FSA who published an independent assessment of 
probiotics in 2003 (Gibson 2003). However, in this analysis they set out to compare the 
viability of individual strains of bacteria rather than commercial products. Other individual 
studies have simply looked at one product in isolation or individual strains of bacteria in 
isolation or have used test systems that may have little relevance for the in vivo situation  
(Corcoran et al. 2005; Huang and Adams 2004; Iyer and Kailasapathy 2005; Oozer et al. 
2006, Sabikhi et al. 2010; Sun and Griffiths 2000).  
There is a wealth of probiotics products currently on the market, including single strain and 
multistrain products, lyophilised capsule or powders, dairy based liquids and a water based 
liquid. Faced with such a huge array of products, choice of which product to use is difficult. 
Factors that affect choice include viability claims both about content and at the site of action. 
It is important that proper product quality control is conducted to ensure that the content 
claims of labels are actually present at the time the product reaches a patient. Further claims 
about gastric survival can only be upheld in test systems that more closely mimic the real-life 
situation, since these will provide the most relevant results for which product to choose and 
how best to use it. In-vivo the bacteria have to transit the small intestine before reaching their 
desired site of action. If concentrations of healthy bacteria are low after gastric transit the 
likelihood of any surviving to grow in the large intestine is low.  
Our study has several limitations; we only looked at one factor affecting viability of the 
products tested and we did not test intestinal transit or the adhesive properties of the bacteria 
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in the colon, both crucial factors that will affect survival and functionality.  In addition we did 
not set out to test an exhaustive list of all products available and as a result our 
generalisations about product groups could be erroneous. While PGF appeared to be the most 
bio-relevant fluid tested, the pH of this fluid was higher than that generally seen in the fasted 
human stomach since this was taken from a freely fed animal. In our PGF test systems 
volume was therefore only variable factor between the fed and fasted state. The calorimeter 
has limitations too; the main drawback is its lack of sensitivity since it is unable to measure 
numbers below 106 CFU/mL.   
Summary 
This study was designed to explore the comparative health and survival of different 
commercial probiotics at two stages of use; at the point of consumption and following 
exposure to gastric fluid models. The results show that at the point of consumption, liquid 
probiotic products contain close to or in excess of their claimed content and in addition, show 
better tolerance to gastric juice relative to many of their dried counterparts. Our real-time 
studies also suggest that the proportions of bacteria that survive gastric transit could be less 
than expected from plate-count analysis and potentially less than would be necessary for 
survival during the next stage of transit through the small intestine, so potentially 
compromising functionality. The study also highlight the importance of good administration 
recommendations; probiotics are likely to have greater viability if taken in the fasted state and 
currently only one product recommends this on its labelling.  
Our recommendations from this study are that gastric tolerance testing should be conducted 
in models that most closely mimic the real-life situation since these will provide us with the 
most relevant results. Tools that allow us to investigate real-time results add to our 
understanding and can be of great benefit. 
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Table 1. Commercial probiotics investigated in this study 1	  
Product 
 
Form Probiotic strains Volume or 
weight 
measured 
per 
content or 
dose 
Claimed 
culture 
concentrati
on 
Dosage/ 
administration 
instructions 
Actimel Liquid 
(Dairy-
based) 
L. casei DN 114 001 
Also, L. bulgaricus 
and Streptococcus 
thermophilus 
100 ml 10 billion 
per 100 ml 
One bottle per 
day as part of 
breakfast 
Align Solid 
(Capsule) 
B. infantis 35624 0.174 g 1 billion per 
capsule 
One capsule per 
day 
Biobala
nce 
support 
Solid 
(Capsule) 
B. bifidum, L. 
acidophilus, and B. 
lactis 
0.300 g 12.5 billion 
per capsule 
Capsules are to 
be taken once 
daily with 
liquid 
Bio-kult Solid 
(Capsule) 
Bacillus subtilis 
PXN21, 
Bifidobacterium spp 
(B.bifidum PXN23, 
B. breve PXN25, B. 
infantis PXN27), 
Lactobacillus spp. 
(L. acidophilus 
PXN3, L. delbrueckii 
spp.bulgaricus 
PXN39, L. casei 
PXN37, L. plantarum 
PXN47, L. 
rhamnosus PXN54, 
L. helveticus PXN45, 
L. salivarius 
PXN57), 
Lactococcus lactis 
spp. Lactis PXN63, 
Streptococcus 
thermophilus PXN66. 
0.171 g 2 billion per 
capsule 
One or two 
capsules, once 
or twice daily. 
Capsule can be 
opened and the 
contents can be 
sprinkled on 
food, taken in a 
drink or 
swallowed 
whole 
Probio 7 Solid 
(Capsule) 
L. casei, L. 
rhamnosus, L. 
plantarum, L. 
acidophilus, 
Streptococcus 
thermophilus, B. 
bifidum, B. breve and 
B. longum. 
0.439 g 10 billion 
per capsule 
One capsule per 
day. Capsule 
should be 
swallowed 
whole 
Sympro
ve 
Liquid 
(Non-
dairy, 
water-
L. rhamnosus, L. 
planatarum, L. 
acidophilus, and 
Enterococcus 
60mL 
taken from 
500 mL 
bottle  
10 billion 
per 50 ml 
1 ml per 
kilogram of 
bodyweight as 
a liquid drink to 
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 2	  
  3	  
based) faecium be taken prior 
to food in the 
morning 
VSL#3 Solid 
(powdered 
sachet) 
Streptococcus 
thermophiles DSM 
24731, B. breve 
DSM 24732, B. 
longum DSM 24736, 
B. infantis DSM 
24737, L. 
acidophilus DSM 
24735, L. plantarum 
DSM 24730, L. 
paracasei DSM 
24733 and L.  
delbrueckii subsp. 
bulgaricus DSM 
24734. 
4.447 g 450 billion 
per sachet 
One sachet, 
once or twice 
daily. Sachets 
can either be 
sprinkled on 
food or 
reconstituted 
with cold water 
or any non-
fizzy drink and 
consumed 
Yakult Liquid 
(Dairy-
based) 
L. casei Shirota 65 mL 6.5 billion 
per 65 mL 
One or two 
bottles per day 
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Table 2. Buffer capacity, osmolality, pH and surface tension of PGF, the simulated 4	  
gastric fluids and human gastric fluid 5	  
 6	  
a Evans et al. 1988 7	  
b Fordtran et al. 1973 8	  
c Kalantzi, et al, 2006 9	  
d Efentakis and Dressman 1998 10	  
** PGF was taken from a freely fed animal; volume was the only variable for the fed versus 11	  
fasted test system 12	  
+FaSSGF is made to pH 1.6 to represent the fasted state.  13	  
 14	  
Simulated 
fluid 
pH Buffer capacity 
(mmol.L-1.∆pH-1) 
Osmolality 
(mOsm.Kg-1) 
Surface tension 
(mN.m-1) 
PGF** 3.381 ± 0.031 12.85 ± 0.684 255.333 ± 0.577 46.075 ± 2.552 
SGF* 1.2 1.211 ± 0.022 43.333 ± 0.714 255.667 ± 0.577 74.175 ± 3.562 
FaSSGF 1.6+ 1.599 ± 0.008 41.7 ± 0.404 138.000 ± 1.000 52.038 ± 2.202 
SGF* 3.4 3.363 ± 0.020 1.7 ± 0.424 82.25 ± 1.8930 73.183 ± 0.248 
FaSSGF 3.4 3.372 ± 0.036 1.233 ± 0.236 83.50 ± 1.9149 65.383 ± 1.864 
Human 
gastric fluid 
1- 2.5 a  
up to 5 (fed)b 
7-18 (fasted)c 
14-28 (fed)c 
559-217c 30-31c 
35-45d 
